A Phase III, Multicentre, Randomised, Double-blind, Chronic Dosing, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease

Administered By

Awarded By

Contributors

Start/End

  • December 8, 2021 - May 20, 2024